secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K/A
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-127218
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA posts $15.7M net loss through Q3 2024; convertible debt rises to $24.4M
------------------------------------------------------------------------------

- Net loss of $15.7M for nine months ended Sep 30, 2024 vs $26.6M prior year (prior year included $16.2M IPR&D charge).
- Operating loss of $12.0M vs $27.1M YoY; R&D spend up to $9.4M from $7.5M.
- Cash position $19.6M at Sep 30, 2024, up from $3.7M year-end 2023 after $28.6M convertible note issuance.
- Convertible notes payable net of discount total $24.4M; derivative liability of $2.9M recorded.
- Stockholders' deficit worsened to $(2.8M) from $(1.6M); closed merger with Kintara on Oct 18, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024127218/0000950170-24-127218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024127218/hura-20241018.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer